Multiple Myeloma Clinical Trial

Study of ENMD-2076 in Patients With Multiple Myeloma

Summary

The study is designed to assess the safety, tolerability, maximum tolerated dose, and clinical benefit of treatment with ENMD-2076 administered orally once daily over a range of doses in patients with relapsed or refractory multiple myeloma.

View Full Description

Full Description

The study is designed to assess the safety, tolerability, maximum tolerated dose, and clinical benefit of treatment with ENMD-2076 administered orally once daily over a range of doses in patients with relapsed or refractory multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Major Inclusion Criteria:

Histological evidence of MM and evidence of relapse or refractory disease. Patients with non secretory myeloma or plasmacytoma only will be excluded.
Patients must have failed thalidomide, lenalidomide, or velcade or be intolerant or ineligible to receive these agents.
Age ≥18 years.
ECOG performance status 0-2.
Patients must have adequate organ and marrow function

Major Exclusion Criteria:

Prior cytotoxic chemotherapy or investigational agent within 28 days or autologous stem cell transplant within 6 months of receiving study drug ENMD-2076.
Prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis).
Concomitant corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.
Have unstable angina pectoris or recent myocardial infarction (within 6 months.
Have uncontrolled hypertension or congestive heart failure.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

13

Study ID:

NCT00806065

Recruitment Status:

Completed

Sponsor:

CASI Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Indiana University Melvin and Bren Simon Cancer Center
Indianapolis Indiana, 46202, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

13

Study ID:

NCT00806065

Recruitment Status:

Completed

Sponsor:


CASI Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.